COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00545259
Recruitment Status : Completed
First Posted : October 17, 2007
Last Update Posted : February 11, 2020
Information provided by:

Brief Summary:
The study will evaluate the pharmacokinetic profile of AEB071 in the immediate post-transplant period in patients who have undergone their first liver transplant.

Condition or disease Intervention/treatment Phase
de Novo Liver Transplantation Drug: AEB071 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Open-label, Two-period, Multi-center, Single Dose Study to Assess the Pharmacokinetics of AEB071 in de Novo Liver Transplant Patients
Study Start Date : October 2007
Actual Primary Completion Date : February 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Drug: AEB071

Primary Outcome Measures :
  1. -Pharmacokinetic of AEB071 & its primary metabolite, AEE800 at predose & up to 72 hours post-operatively -Safety & tolerability (vital signs,ECGs,clinical lab evaluations,seroius/adverse events) -AEB071,AEE800 & tacrolimus in blood for both Periods [ Time Frame: at predose & 16 timepoints post-dose ]

Secondary Outcome Measures :
  1. -Pharmacokinetics of tacrolimus in presence of AEB071 -Biliary excretion of AEB071 & primary metabolite (AEE800) from patients with a T-tube -Relationship of free drug concentration, α-1 acid glycoprotein concentration & pharmacokinetics AEB071

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary liver transplant recipients.
  • Transplanted liver functioning at an acceptable level by 24 h post-transplant
  • Patients started on tacrolimus therapy within 12 h post-transplant

Exclusion Criteria:

  • Previous transplantation or multiple organs transplantation
  • Acute rejection
  • Non-heart beating donor

Other protocol-defined inclusion/exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00545259

Layout table for location information
Novartis investigative site
Berlin, Germany
Novartis Investigative Site
Padova, Italy
Novartis investigative site
Zurich, Switzerland
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Novartis Investigator site
Additional Information:
Layout table for additonal information
Responsible Party: External Affairs, Novartis Identifier: NCT00545259    
Other Study ID Numbers: CAEB071B2101
First Posted: October 17, 2007    Key Record Dates
Last Update Posted: February 11, 2020
Last Verified: February 2008
Keywords provided by Novartis:
Organ transplant, liver, pharmacokinetics, AEB071, immunosuppression